UPDATE: Credit Suisse Reiterates On Biogen Idec On Gilenya PPMS Risk

In a report published Wednesday, Credit Suisse analyst Ravi Mehrotra reiterated an Outperform rating on

, but lowered the price target from $425.00 to $400.00. In the report, Credit Suisse noted, “We have separately published today a note titled ‘Get INFORMed – PPMS Gilenya – Potential Significant Impact on All MS Players'. Concomitantly, we are reducing our BIIB TP to $400 to take into account the ‘Gilenya PPMS' risk described in the deep dive, but retain an Outperform recommendation based on our standing view of premium to large cap biotech and S&P warrant by quality and magnitude of revenue earnings growth, domain domination, pipeline (esp anti-LINGO) and 2015 capital allocation upside. Our $400 TP corresponds to 26x 2015 EPS (65% premium to the S&P500's 16x) vs. our previous TP of $425 (which is a 75% premium).” Biogen Idec closed on Tuesday at $305.56.